Q-omics provides the consensus-scored CCNB3 profile across patient tissues and cancer cell-line models. CCNB3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CCNB3 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, CCNB3 RNA expression shows 18,059 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, THCA, and UVM as cancer lineages where CCNB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNB3 survival associations across molecular data types. CCNB3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNB3 RNA expression–survival associations across cancer types. High CCNB3 expression shows unfavorable associations in LUSC, KICH and UVM, but favorable associations in MESO, LGG and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for CCNB3 RNA expression.
This table summarizes CCNB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCNB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNB3 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BRCA, CHOL and STAD. The THCA box plot shows higher CCNB3 RNA expression in normal versus tumor tissue (log2 FC = −0.287, t-test p < 0.001).
This table shows molecular features associated with CCNB3 in patient tissues and cancer cell lines. In patient samples, CCNB3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCNB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
